TherapeuticsMD Announces First Quarter 2023 Financial Results

TherapeuticsMD Announces First Quarter 2023 Financial Results

BOCA RATON, Fla. May 15, 2023 TherapeuticsMD, Inc. ( TherapeuticsMD or the Company )

(NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2023.

First Quarter 2023 Financial Results

Continuing Operations

License and Service Revenues from Continuing Operations

Total Operating Expenses from Continuing Operations

Discontinued Operations

The Company continues to wind down its former commercial operations and to focus on reducing costs.

About TherapeuticsMD

TherapeuticsMD was previously a

women s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. In December 2022, the Company changed its business to become a

pharmaceutical royalty company, primarily collecting royalties from its licensees. The Company is no longer engaging in research and development or commercial operations.

Forward-Looking Statements

This press release by

TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD s objectives, plans and strategies as well as statements, other than historical

facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as believes,

hopes, may, anticipates, should, intends, plans, will, expects, estimates, projects, positioned, strategy

expressions and are based on assumptions and assessments made in light of management s experience and perception of historical trends, current conditions, expected future developments and

other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new

information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company s control. Important factors that could cause

actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled Risk Factors in the company s filings with the Securities and Exchange Commission,

including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and

include the following: whether Mayne Pharma will be successful at commercializing the products that it licensed and acquired from TherapeuticsMD; whether the company is successful in winding down its operations and the costs associated therewith,

including the company s ability to obtain any additional financing necessary therefor and any adjustments to the net working capital purchased as part of the Mayne Pharma transaction; whether the company is successful in identifying strategic

pathways to create additional shareholder value; the company s ability to remain listed on Nasdaq; the impact of product liability lawsuits; the impact of leadership transitions; and the volatility of the trading price of the company s